Nivolumab and pembrolizumab as anti‐PD‐1 antibody and atezolizumab as PD‐L1 antibody, the immune checkpoint inhibitor (ICI), have proved their efficacy and safety in patients with pretreated advanced NSCLC in clinical trials.4, 5, 6. This evidence concerns the gene CD274 and non-small cell lung carcinoma.